SCHEMBL501238

SCHEMBL501238

O=C(O)c1cn(C2CC2)c2cc(F)c(F)cc2c1=O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.69
ALDH1A1 P00352 5/20 0.69
TOP2A P11388 5/20 0.69
TOP2B Q02880 5/20 0.69
LMNA P02545 3/20 0.69
HPGD P15428 2/20 0.69
HSD17B10 Q99714 2/20 0.69
CYP1A2 P05177 1/20 0.69
CYP2C9 P11712 1/20 0.69
MAPT P10636 1/20 0.65
PIK3CG P48736 5/20 0.55
PIK3CD O00329 4/20 0.55
PIK3R1 P27986 4/20 0.55
PIK3CA P42336 4/20 0.55
HTT P42858 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
POLB P06746 1/20 0.51
CHRM2 P08172 1/20 0.51
CHRM1 P11229 1/20 0.51
OPRM1 P35372 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29442121 1.00 KDM4E (0.69) KDM4EALDH1A1TOP2ATOP2BLMNA
Fluoride SCHEMBL5143436 0.97 KDM4E (0.66) KDM4EALDH1A1TOP2ATOP2BLMNA
SCHEMBL5143438 0.96 KDM4E (0.65) KDM4EALDH1A1TOP2ATOP2BLMNA
SCHEMBL1243805 0.94 KDM4E (0.63) KDM4EALDH1A1TOP2ATOP2BLMNA
SCHEMBL6498695 0.94 ALDH1A1 (0.62) KDM4EALDH1A1TOP2ATOP2BLMNA
SCHEMBL4299077 0.91 KDM4E (0.65) KDM4EALDH1A1TOP2ATOP2BLMNA
SCHEMBL10330778 0.89 KDM4E (0.64) KDM4EALDH1A1TOP2ATOP2BLMNA
SCHEMBL10875970 0.89 KDM4E (0.64) KDM4EALDH1A1TOP2ATOP2BLMNA
SCHEMBL2108243 0.89 ALDH1A1 (0.64) KDM4EALDH1A1TOP2ATOP2BLMNA
SCHEMBL4718738 0.89 KDM4E (0.60) KDM4EALDH1A1TOP2ATOP2BLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 381 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4127157-B1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS ENCODIA INC (US) 2026-02-11 EP claimed
US-20240011009-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2024-01-11 US claimed
US-20230220589-A1 POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF Encodia, Inc. (US) 2023-07-13 US claimed
EP-3784656-B1 PROCESS FOR THE HYDROLYSIS OF QUINOLONE CARBOXYLIC ESTERS ELANCO ANIMAL HEALTH GMBH (DE) 2023-06-28 EP claimed
EP-4127157-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2023-02-08 EP claimed
CN-112881542-B Stable isotope deuterium-labeled danofloxacin and synthetic method thereof 上海安谱实验科技股份有限公司 2022-11-18 CN claimed
US-11332444-B2 Method for the hydrolysis of quinolonecarboxylic esters BAYER ANIMAL HEALTH GMBH (DE) 2022-05-17 US claimed
WO-2022072560-A1 POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF Encodia, Inc. (US) 2022-04-07 WO claimed
CN-113912540-A Synthesis method of 1-cyclopropyl-6, 7-difluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid 山东国邦药业有限公司 2022-01-11 CN claimed
WO-2021194908-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2021-09-30 WO claimed
EP-1236718-B1 Improved process for the preparation of fluoro-quinolonecarboxylic acids BAYER CHEMICALS AG (DE) 2004-08-11 EP claimed
US-6590101-B2 Hydrolysis of the corresponding C1-C4-alkyl esters with addition of water, acetic acid, and sulfuric acid using a drastically reduced amount of sulfuric acid BAYER AKTIENGESELLSCHAFT (DE) 2003-07-08 US claimed
EP-1236718-A1 Improved process for the preparation of fluoro-quinolonecarboxylic acids BAYER AG (DE) 2002-09-04 EP claimed
US-20020120138-A1 Process for the preparation of fluoroquinolonecarboxylic acids LANXESS DEUTSCHLAND GMBH (DE) 2002-08-29 US claimed
EP-0775114-B1 PROCESS FOR MAKING ANTIMICROBIAL COMPOUNDS PROCTER & GAMBLE (US) 2000-03-22 EP claimed
US-5703231-A Process for making antimicrobial compounds THE PROCTER & GAMBLE COMPANY (US) 1997-12-30 US claimed
WO-1996004247-A1 PROCESS FOR MAKING ANTIMICROBIAL COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 1996-02-15 WO claimed
EP-0274033-B1 PROCESS FOR THE PREPARATION OF QUINOLINECARBOXYLIC ACIDS BAYER AG (DE) 1992-03-11 EP claimed
US-5095112-A PROCESS FOR THE PREPARATION OF QUINOLONECARBOXYLIC ACID ESTERS BAYER AKTIENGESELLSCHAFT (DE) 1992-03-10 US claimed
EP-0274033-A1 Process for the preparation of quinolinecarboxylic acids BAYER AG (DE) 1988-07-13 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120138-A1 Process for the preparation of fluoroquinolonecarboxylic acids ADH1C, CTRC, ADH1A KDM4E 2934/4885ALDH1A1 124/4885TOP2A 352/4885
US-11332444-B2 Method for the hydrolysis of quinolonecarboxylic esters NQO2, PGD, ALAD KDM4E 2839/4885ALDH1A1 274/4885TOP2A 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.